• SVR - sustained virological response 12 weeks after treatment ended (cure)
  • RBV was weight based - see ribavirin dosing
  • References [1]
HCV genotype 1a response to therapy
Treatment Polymorphism
(M28, Q30, L31, or Y93)
SVR at 12 weeks
(cure)
Zepatier for 12 weeks No 98% (441/450)
Zepatier + RBV for 16 weeks No 100% (49/49)
Zepatier for 12 weeks Yes 70% (39/56)
Zepatier + RBV for 16 weeks Yes 100% (6/6)















  • NS5A polymorphisms affect response to Zepatier. See Zepatier for more.
  • PI = boceprevir, simeprevir, or telaprevir
  • Ribavirin dosing is weight-based (regimen 2)
Patient Treatment Duration
GT 1a: Treatment-naïve or PegIFN / RBV-experienced without baseline NS5A polymorphisms Zepatier 12 weeks
GT 1a: Treatment-naïve or PegIFN / RBV-experienced with baseline NS5A polymorphisms Zepatier + RBV 16 weeks
GT 1b: Treatment-naïve or PegIFN / RBV-experienced Zepatier 12 weeks
GT 1a or 1b: PegIFN / RBV / PI-experienced Zepatier + RBV 12 weeks
GT 4: Treatment-naïve Zepatier 12 weeks
GT 4: PegIFN / RBV-experienced Zepatier + RBV 16 weeks